Cargando…

The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?

SIMPLE SUMMARY: The current review assessed the effects of the gut microbiome on clinical outcomes of immunotherapy and related adverse events (AEs) in cancer patients. Studies (n = 10) consistently reported that the gut microbiome prior to administering immune checkpoint inhibitors (ICIs) was assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Byeongsang, Boyle, Frances, Pavlakis, Nick, Clarke, Stephen, Eade, Thomas, Hruby, George, Lamoury, Gillian, Carroll, Susan, Morgia, Marita, Kneebone, Andrew, Stevens, Mark, Liu, Wen, Corless, Brian, Molloy, Mark, Kong, Benjamin, Libermann, Towia, Rosenthal, David, Back, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508052/
https://www.ncbi.nlm.nih.gov/pubmed/34638308
http://dx.doi.org/10.3390/cancers13194824
_version_ 1784582006982574080
author Oh, Byeongsang
Boyle, Frances
Pavlakis, Nick
Clarke, Stephen
Eade, Thomas
Hruby, George
Lamoury, Gillian
Carroll, Susan
Morgia, Marita
Kneebone, Andrew
Stevens, Mark
Liu, Wen
Corless, Brian
Molloy, Mark
Kong, Benjamin
Libermann, Towia
Rosenthal, David
Back, Michael
author_facet Oh, Byeongsang
Boyle, Frances
Pavlakis, Nick
Clarke, Stephen
Eade, Thomas
Hruby, George
Lamoury, Gillian
Carroll, Susan
Morgia, Marita
Kneebone, Andrew
Stevens, Mark
Liu, Wen
Corless, Brian
Molloy, Mark
Kong, Benjamin
Libermann, Towia
Rosenthal, David
Back, Michael
author_sort Oh, Byeongsang
collection PubMed
description SIMPLE SUMMARY: The current review assessed the effects of the gut microbiome on clinical outcomes of immunotherapy and related adverse events (AEs) in cancer patients. Studies (n = 10) consistently reported that the gut microbiome prior to administering immune checkpoint inhibitors (ICIs) was associated with enhanced efficacy of ICIs and reduced AEs. Recent fecal microbiome transplant (FMT) studies demonstrated the modulatory effects of FMT on the composition and diversity of the gut microbiome in patients with refractory cancers and the potential to improve the efficacy of ICIs. ABSTRACT: Background: Emerging evidence suggests that gut microbiota influences the clinical response to immunotherapy. This review of clinical studies examines the relationship between gut microbiota and immunotherapy outcomes. Method: A literature search was conducted in electronic databases Medline, PubMed and ScienceDirect, with searches for “cancer” and “immunotherapy/immune checkpoint inhibitor” and “microbiome/microbiota” and/or “fecal microbiome transplant FMT”. The relevant literature was selected for this article. Results: Ten studies examined patients diagnosed with advanced metastatic melanoma (n = 6), hepatocellular carcinoma (HCC) (n = 2), non-small cell lung carcinoma (NSCLC) (n = 1) and one study examined combination both NSCLC and renal cell carcinoma (RCC) (n = 1). These studies consistently reported that the gut microbiome profile prior to administering immune checkpoint inhibitors (ICIs) was related to clinical response as measured by progression-free survival (PFS) and overall survival (OS). Two studies reported that a low abundance of Bacteroidetes was associated with colitis. Two studies showed that patients with anti-PD-1 refractory metastatic melanoma experienced improved response rates and no added toxicity when receiving fecal microbiota transplant (FMT) from patients with anti-PD-1 responsive disease. Conclusions: Overall, significant differences in the diversity and composition of the gut microbiome were identified in ICIs responders and non-responders. Our findings provide new insights into the value of assessing the gut microbiome in immunotherapy. Further robust randomized controlled trials (RCTs) examining the modulatory effects of the gut microbiome and FMT on ICIs in patients not responding to immunotherapy are warranted.
format Online
Article
Text
id pubmed-8508052
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85080522021-10-13 The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy? Oh, Byeongsang Boyle, Frances Pavlakis, Nick Clarke, Stephen Eade, Thomas Hruby, George Lamoury, Gillian Carroll, Susan Morgia, Marita Kneebone, Andrew Stevens, Mark Liu, Wen Corless, Brian Molloy, Mark Kong, Benjamin Libermann, Towia Rosenthal, David Back, Michael Cancers (Basel) Review SIMPLE SUMMARY: The current review assessed the effects of the gut microbiome on clinical outcomes of immunotherapy and related adverse events (AEs) in cancer patients. Studies (n = 10) consistently reported that the gut microbiome prior to administering immune checkpoint inhibitors (ICIs) was associated with enhanced efficacy of ICIs and reduced AEs. Recent fecal microbiome transplant (FMT) studies demonstrated the modulatory effects of FMT on the composition and diversity of the gut microbiome in patients with refractory cancers and the potential to improve the efficacy of ICIs. ABSTRACT: Background: Emerging evidence suggests that gut microbiota influences the clinical response to immunotherapy. This review of clinical studies examines the relationship between gut microbiota and immunotherapy outcomes. Method: A literature search was conducted in electronic databases Medline, PubMed and ScienceDirect, with searches for “cancer” and “immunotherapy/immune checkpoint inhibitor” and “microbiome/microbiota” and/or “fecal microbiome transplant FMT”. The relevant literature was selected for this article. Results: Ten studies examined patients diagnosed with advanced metastatic melanoma (n = 6), hepatocellular carcinoma (HCC) (n = 2), non-small cell lung carcinoma (NSCLC) (n = 1) and one study examined combination both NSCLC and renal cell carcinoma (RCC) (n = 1). These studies consistently reported that the gut microbiome profile prior to administering immune checkpoint inhibitors (ICIs) was related to clinical response as measured by progression-free survival (PFS) and overall survival (OS). Two studies reported that a low abundance of Bacteroidetes was associated with colitis. Two studies showed that patients with anti-PD-1 refractory metastatic melanoma experienced improved response rates and no added toxicity when receiving fecal microbiota transplant (FMT) from patients with anti-PD-1 responsive disease. Conclusions: Overall, significant differences in the diversity and composition of the gut microbiome were identified in ICIs responders and non-responders. Our findings provide new insights into the value of assessing the gut microbiome in immunotherapy. Further robust randomized controlled trials (RCTs) examining the modulatory effects of the gut microbiome and FMT on ICIs in patients not responding to immunotherapy are warranted. MDPI 2021-09-27 /pmc/articles/PMC8508052/ /pubmed/34638308 http://dx.doi.org/10.3390/cancers13194824 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Oh, Byeongsang
Boyle, Frances
Pavlakis, Nick
Clarke, Stephen
Eade, Thomas
Hruby, George
Lamoury, Gillian
Carroll, Susan
Morgia, Marita
Kneebone, Andrew
Stevens, Mark
Liu, Wen
Corless, Brian
Molloy, Mark
Kong, Benjamin
Libermann, Towia
Rosenthal, David
Back, Michael
The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
title The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
title_full The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
title_fullStr The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
title_full_unstemmed The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
title_short The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
title_sort gut microbiome and cancer immunotherapy: can we use the gut microbiome as a predictive biomarker for clinical response in cancer immunotherapy?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508052/
https://www.ncbi.nlm.nih.gov/pubmed/34638308
http://dx.doi.org/10.3390/cancers13194824
work_keys_str_mv AT ohbyeongsang thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT boylefrances thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT pavlakisnick thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT clarkestephen thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT eadethomas thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT hrubygeorge thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT lamourygillian thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT carrollsusan thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT morgiamarita thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT kneeboneandrew thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT stevensmark thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT liuwen thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT corlessbrian thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT molloymark thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT kongbenjamin thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT libermanntowia thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT rosenthaldavid thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT backmichael thegutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT ohbyeongsang gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT boylefrances gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT pavlakisnick gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT clarkestephen gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT eadethomas gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT hrubygeorge gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT lamourygillian gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT carrollsusan gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT morgiamarita gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT kneeboneandrew gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT stevensmark gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT liuwen gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT corlessbrian gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT molloymark gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT kongbenjamin gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT libermanntowia gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT rosenthaldavid gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy
AT backmichael gutmicrobiomeandcancerimmunotherapycanweusethegutmicrobiomeasapredictivebiomarkerforclinicalresponseincancerimmunotherapy